On the other hand, point mutations in RET gene are common in sporadic medullary thyroid cancer (MTC), in 60–90% of patients, and in multiple endocrine neoplasia syndrome type 2 (MEN2) [3,4,5]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.